Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences.

This development marks a significant achievement for Enveric Biosciences in safeguarding its intellectual property. Patents are core assets for biotechnology companies, and successfully defending them helps protect the value of the company's R&D investments and future market potential. With the withdrawal of the challenge, Enveric Biosciences can now focus more on advancing its pipeline of therapeutics for neuropsychiatric disorders.